Challenge of adolescent male CD-1 mice with a coxsackievirus B3 (CVB3) strain (CVB3,) induces mild to severe destruction of pancreatic acinar cells, but causes no deaths and does not induce hyperglycemia. A weekly parenteral (intraperitoneal) administration of a glyconutritional mixture (Ambrotose | to virus-challenged mice was assessed to determine if there were any benefits to recovery over an eight month period. Virus-challenged mice showed a significant weight loss over the initial five weeks of the experiment, but injection of Ambrotose | to similar virus-challenged mice restored the total body weight to levels found in normal mice. Normal mice given Ambrotose | exhibited a small weight gain. Mice given Ambrotose | showed reduced severity of pancreatitis, as evidenced by significant reductions in percentages of pancreatic acinar cells destroyed and proportion of sections of pancreata with destroyed acinar cells, compared to virus control-mice not injected with Ambrotose | Statistical analyses of the extent of acinar cell pathology in all virus-challenged mice showed that Ambrotose | contributed significantly to recovery of the acinar cell population in virus-inoculated mice. Anti-viral antibody titers were not affected by Ambrotose | injections. One potential mechanism to explain the benefits derived from Ambrotose | injections came from studies of antioxidant levels of glutathione in splenic macrophages/monocytes. Whereas CVB3 challenge of mice reduced glutathione levels in the latter cells, Ambrotose | injections to viruschallenged mice restored glutathione levels to those found in normal mice. In summary, most but not all mice derived benefits from Ambrotose | injections, i.e. a reduction in pathology in the pancreas and restored levels of the antioxidant glutathione in macrophages/monocytes. Higher doses of Ambrotose | could provide greater benefits for more mice, a study for the future.
INTRODUCTION
The coxsackieviruses of group B (CVB) have long been associated with pancreatitis and some cases of insulindependent diabetes mellitus (IDDM; Pallansch, 1988; Melnick, 1997) . Between 40 and 80 percent of adults in the U.S. have been infected with one of the five serotypes (of six total) of CVB that are endemic in the U.S., and 10-30 percent have been infected with two or three serotypes (Pallansch, 1988) . Infection results in a wide range of documentable illness only 10 percent of the time, but actual morbidity is likely much higher because many illnesses are not reported, do not require hospitalization, or the disease may have long latent periods, e.g., IDDM (Paliansch, 1988) . Sadly, CVB infections in infants and young children can be fatal (Cherry, 1995) .
Strains of several CVB serotypes can induce pancreatitis in mice, an excellent animal model of the disease in humans (Pappenheimer et al., 1951; Ross et al., 1974; Lansdown, 1976; Webb and Madge, 1980; Kuno et al., 1984) . Severity of disease induced depends upon virulence determinants in the genotype of the infecting strain (Ramsingh et al., 1989; Caggana et al., 1993; Ramsingh and Collins, 1995) . Molecular studies of one well-characterized strain of coxsackievirus B4 (CVB4) showed that changes in single amino acids in either of two of the four capsid polypeptides of the virion could significantly affect the capacity of the virus for inducing pancreatitis in mice (Caggana et al., 1993; Ramsingh and Collins, 1995) . Infection of mice by a CVB4 can profoundly alter lymphocyte repertoires prior to onset of either hypoglycemia or hyperglycemia (Chatterjee et al., 1992) and autoantibodies are induced that cross react with viral antigens and glutamic acid dehydrogenase (GAD65) in beta cells of the islets of Langerhans (Atkinson et al., 1994; Hou et al., 1994; Jones and Crosby, 1996; Lonnrot et al., 1996) . Increased expression of GAD65 in the islets of CVB4-infected mice has been found during active early virus infection at that site. The genetic background of the murine strain involved in the CVB4-mouse response to infection also plays a major role in determining whether or not pancreatitis/IDDM is induced and severity of disease induced (Lansdown, 1976; Webb and Madge, 1980; Ramsingh et al., 1989; Tisch et al., 1993) .
Pancreatitis describes a diverse group of diseases in which injury to acinar cells of the exocrine pancreas precedes an inflammatory response directed toward the pancreas (Grendell and Egan, 1987; Steer and Meldolesi, 1988; Regan and Go, 1990; Leach et al., 1992; Bockman, 1997) . Although the etiology of pancreatitis is most likely multiple, the majority of diagnosed cases of pancreatitis have been associated with either biliary obstruction or chronic alcohol abuse (Reber, 1987; Bilchik et al., 1990; Regan and Go, 1990) . Over one-third of the 80,000 annual cases in the U.S. are idiopathic, or attributed to several clinical situations, including infections (Reber, 1987; Bilchik et al., 1990; Regan and Go, 1990) . Chronic alcohol abuse is considered a major co-factor, as up to 74 percent of patients are considered alcoholics (Reber, 1987) . Current clinical treatment for pancreatitis has not changed over the past twenty years and largely consists of nonspecific supportive therapy (Grendell and Egan, 1987; Leach et al., 1992) .
The human pancreas has evolved into an organ with remarkable regenerative capabilities following acute pancreatitis (Bockman, 1997) . Acinar cells of the exocrine pancreas can undergo dedifferentiation to form ductules and tubular complexes (Hall and Lemoine, 1992; Bockman, 1997) . Epithelial cells in the ducts and tubular complexes apparently have pleuripotential capabilities (Lechene et al., 1991 ; Iovanna et al., 1992) , and can differentiate to become several types of cells comprising the pancreas, including endocrine cells (Gu et al., 1994) . Thus in the regenerating pancreas, acinar cells have multifunctional capabilities that are highly significant to the recovery process (Bockman, 1995; Bockman, 1997) .
In a retrospective study of the effects of nutraceutical dietary intervention in humans with IDDM or noninsulindependent diabetes mellitus, a mixtu re of glyconutritional (Ambrotose| phytonutritional (Phyt-AloeTM), phytogenin (PLUS) and food-based vitamins/minerals was found to have significant benefits for these patients . The benefits included increases in health and an improved sense of well-being, decreases in Candida infections, decreases in other recurrent/persistent infections, resolution of vision problems, reduction in high blood pressure, and resolution of gastrointestinal tract problems and numbness, pain or burning in the lower extremities . The challenge of understanding the mechanism(s) by which supplemental dietary nutraceuticals are beneficial in recovery from acute pancreatitis suggested an examination of the potential of parenteral administration of the glyconutrient mixture Ambrotose ~ on coxsackievirus B3 (CVB3)-induced long-term (8 months) pancreatitis in a murine model of the disease. Data from the present study suggest that Ambrotose | did have an ameliorative effect in this virus-animal model, perhaps as an antioxidant working through macrophages. Whereas free glutathione (GSH) levels in splenic monocytes/macrophages were generally depressed in CVB3-inoculated mice, compared to normal mice, over an 8 month period of study, weekly inoculations of Ambrotose | restored free glutathione levels in these cells to levels found in macrophages/monocytes from normal mouse spleens.
MATERIALS AND METHODS
Mice. Male adolescent (4 weeks of age) mice of the CD-1 strain were purchased from Charles River Breeding Laboratories, Boston, MA. All mice were maintained in Laboratory Animal Resources facilities of the University of Texas Health Science Center at San Antonio. Water and laboratory mouse chow were available ad libitum to all mice. Mice were rested three days after arrival.
Virus. The highly myocarditic CVB3 m variant is a Nancy strain prototype (Trousdale et al., 1979) . CVB3 m was propagated and assayed for infectious virus titers by a plaque method in HeLa cells (Gauntt et al., 1995) .
Ambrotose ~. Bulk Ambrotose ~ was provided as a lyophilized powder, filler-free, Lot #550-1080, from Mannatech, Inc., Coppell, TX and rehydrated with sterile DPBS on the day of use.
Histology. Coronal sections of pancreata were stained with hematoxylin and eosin and duplicate sections scored blind by two reviewers for extensive (_> 90%) acinar cell destruction or categories of <90-50, 50-10 <10 or no scores given on acinar cell destruction at magnifications of 100 and 200X. Sections of pancreata reflect a conservative consensus of outcome; where there was a disagreement on % cells destroyed, the lower number was reported.
Virus neutralization assays. The highly sensitive cytopathic effects (cpe)-inhibition assay for anti-CVB3 antibodieswas previously described (Godenyet al., 1988) . In this assay, a volume of virus at 2 x 10 s pfu/ml was mixed with an equal volume of a dilution of a serum (heatinactivated) and the sealed mixture was held in a 37 ~ incubator for 30 min. All dilutions of sera were made using virus growth medium (VGM; MEM containing 1% heatinactivated fetal bovine serum and antibiotics). Aliquots (0.1 ml) of each mixture were inoculated in triplicate onto monolayer cultures of 10-20,000 HeLa cells per well in 96 well tissue culture plates, and the cultures were incubated for 24-36 hr at 37 ~ until the virus control culture exhibited complete destruction. Cultures receiving diluted serumvirus mixtures were then scored as (-) for complete protection, 1+ to 3+ for partial protection of cells or (4+) which indicated no protection of cells, i.e., total cell destruction. The serum dilution which protected at least 50% or greater (2+ score) of cells in at least 2 of the 3 wells was taken as endpoint, and the reciprocal of the mean of the dilution at endpoint was taken as the titer.
Glucose concentrations. Glucose concentrations were determined in triplicate on heat-inactivated serum samples using an Ames Glucometer 3" (Miles Inc., Diagnostics Division Elkhart, IN) according to the manufacturers directions. Values obtained by this method were very similar (< 5%) to values obtained by a standard hexokinase method (Bondar and Mead, 1974) . Cellular glutathione levels. Cellular glutathione (GSH) levels were evaluated in attached splenic monocytes/ macrophages with monochlorobimane (mBCI; Molecular Probes, Inc., Eugene, OR) using a laser scanning Meridian Ultima confocal microscope (Meridian Instruments, Inc., Okemos, MI). The cell-permeant mBCI probe is non-fluorescent, but forms a fluorescent conjugate with GSH in a reaction catalyzed by glutathione Stransferase (Rice et al., 1986; Shrieve et al., 1988) . The microscope was used at an excitation wavelength of 351-363 nm, and emitted fluorescence at 461 nm was detected using a barrier filter (BP 485/45). Excitation and detection parameters were kept constant for all GSH experiments. For image capture, the laser excited fluorescence in cells from a two-dimensional raster pattern (scan parameters were optimized for maximum detection of fluorescence with minimum cellular photobleaching). Kinetic analysis of mBCI-GSH conjugation was performed at room temperature on the Ultima stage by recording changes in fluorescence intensity at 15-sec intervals for approximately 15 rain (Barhoumi et al., 1995 , Busbee et al., 1999 .
Experimental protocol. After resting for 3 days after arrival, mice were injected with Ambrotose | at 10mg/kg body weight, diluted in Dulbecco's phosphate-buffered saline (DPBS), or DPBS alone on day -7 by the intraperitoneal (i.p.) route. On day 0, half of the group of mice administered Ambrotose | and half of the control (DPBS only) groups were inoculated with 5 x 10 ~ plaque-forming units (PFU) of virus by i.p. route. The remaining half of each group were administered DPBS only. Approximately every 7 days thereafter, half of all mice were injected by i.p. route with Ambrotose | at doses of 10mg/ kg body weight or the other half were injected with DPBS. On select days post-inoculation (p.i.), each mouse was weighed. Generally seven randomly selected mice were deeply anesthetized (Metafane) and humanely sacrificed. Sera from individual mice were stored for antMral antibody titer assays. Pancreata were quickly removed and fixed in buffered 10% formalin. Spleens were removed and processed to obtain attached monocytes/macrophages for GSH levels as above.
RESULTS

Effect of Parenteral AdministraUon of Ambrotose ~ on Total Body Weights in Normal and Virus-Challenged Mice.
Over the first five weeks post-inoculation of virus, most virus-challenged mice exhibited a significant total body weight loss, compared to normal mice (Table 1) . Thereafter, virus-challenged mice had similar total body weights as normal mice. Beginning around week four post-virus challenge and for the next three weeks, the group of mice receiving Ambrotose | showed significant recovery in whole body weight losses to achieve body weights similar to those found in normal mice; this weight recovery remained for the next 6 months. However, normal mice receiving Ambrotose | also showed significant weight gain beginning around week four and this significantly increased weight (greater than that of normal mice) was maintained for the next six weeks. Thereafter, weight differences were not always significant between the two groups. The transient six week weight gain promoted by Ambrotose | in normal mice amounted to about an 8% increase in total body weight.
Ambrotose ~ Effects Faster Recoveryfrom CVB3-1nduced
Pancreatitis in Mice. Islets showing inflammation were found rarely and sporadically in pancreata of CVB3 minoculated mice, regardless of whether the mice were exposed to Ambrotose | or not (Gauntt and Wood, data not shown). Weekly administration of Ambrotose | generally appeared to reduce both the number of pancreas sections with any acinar cell destruction and the severity of acinar cell destruction per pancreas section, compared to similar parameters in the virus-challenged control group ( Table  2) . Photomicrographs of typical stained (hematoxylin and eosin) sections of pancreas that show five categories of % of acinar cells destroyed in pancreata of CVB3-inoculated mice (>90%; <90-50%; <50-10%; <10%; and none) are presented in Figure 1 . On day 28, four weeks after virus challenge there were no significant differences in either parameter between Ambrotose| and nontreated groups of CVB3m-inoculated mice. It was not until week 7 post virus challenge that the proportion of acinar cells (two sections per mouse pancreas) in mice given Ambrotose | showed a significant reduction in pathologic alterations. Thereafter, pancreata taken from Ambrotose| groups of mice at three of four times of sacrifice had either a significant reduction in number of sections of pancreata with any destruction of acinar cells (weeks 10, 19 and 35.5 post-inoculation) or both a reduction in number of pancreas sections with any acinar cell destruction and a reduction in proportion of acinar cells destroyed to <10% or none (week 19), compared to groups of virus-challenged mice not receiving injections of Ambrotose | Note that at 5 of 6 times of assay (day 70 being the exception), levels of GSH in splenocytes from virus-infected mice were reduced to 67-79% of levels found in splenocytes from normal mice. In contrast, note that at the same 5 times of assay, splenocytes from Ambrotose| virus-challenged mice contained 19-97% more GSH than splenocytes from untreated virus-challenged (virus control) mice. These data also show that there were a few mice in each of the groups receiving Ambrotose | treatment that derived no benefit from the glyconutritional mixture, regardless of the number of weeks of dietary supplementation. One mouse even had extensive destruction of pancreatic acinar cells after Ambrotose | administration continuouslythrough week35.5. Because no mice died during the experiment and Chi Square comparative analyses of the effect of Ambrotose | on virusinduced destructive processes relative to the proportion of pancreas sections with no or <10% of acinar cells destroyed versus the extent of pathology in the pancreata of control mice showed significant differences (p=0.05), the data suggest that some outbred mice, like some humans cannot derive health recovery On day-7, 25 random mice were weighed before assignment to one of the four groups. Half of the mice were injected with buffer (DPBS) and half with Ambrotose | at 10mg/kg body weight in DPBS on day -7 post-inoculation (p.i.). On day 0, one group of normal mice (Virus group) and one group of Ambrotose | injected mice were challenged with 5x105 plaque-forming units of purified CVB3 per mouse. On designated days p.i., all mice in each of the groups were weighed and the number decreased as 7 mice per group were withdrawn for sacrifice. Thus, up through day 28 p.i., there were 45 mice/group; through day 49 p.i., 38 mice per group; through day 70 p.i., 31 mice/group; through day 105 p.i., 24 mice per group and through day 133 p.i., 17 mice/group. After weighing, mice were inoculated with DPBS or Ambrotose | on the day indicated. Serum Glucose Levels. CVB3r, challenge of male CD-1 mice did not affect levels of glucose in these mice between four and 35.5 weeks post-inoculation (Table 3) . These data confirm previous findings (Reyna, Wood and Gauntt, unpublished data) that CVB3 m challenge of this strain (CD-1) of mouse does not induce diabetes mellitus type I. Administration of Ambrotose | weekly to normal or virus-inoculated mice also did not significantly alter glucose levels.
Effect of Ambrotose ~ Injections on Anti-CVB3 Antibody
Titers. Recent work (Gauntt et al., 1999) has shown that aloe polymannose significantly enhanced anti-CVB3 m antibody titers in mice and previous studies showed that mice that produced faster or higher titers of anti-CVB3 antibodies in response to virus challenge had reduced virus-induced acute cardiopathologic alterations compared to mice that delayed or had reduced production of anti-CVB3 antibodies (Gauntt, 1997) . Therefore, it was of interest to assess antiviral antibody titers in mice given Ambrotose | particularly to determine if this glyconutritional mixture could stimulate anti-CVB3 antibody titers at early times post virus-challenge. The data (Table 4) show that serum CVB3-neutralizing antibody titers from individual mice varied over a wide range at each time of assay, leading to very large standard deviations for the small geometric mean antibody titers. Ambrotose ~ administration had no effect on anti-CVB3 antibody titers at any time over this 8 month experiment. (Reiss and Komatsu, 1998) , including CVB3 (Freeman et al., 1998) , induce synthesis of nitric oxide synthetase during infection of cells. CVB3-infected cells in murine heart tissues infected in vivo also attract macrophages and neutrophils that express high levels of this enzyme (Hiraoka et al., 1996; Lowenstein et al., 1996) , thus increasing the overall levels of NO, an oxidant (Dawson and Dawson, 1994) in the infected tissue. Dietary supplementation with a variety of antioxidant materials has proven beneficial in a variety of diseases (Maxwell, 1 995; Barhoumi et al., 1997) . Cell systems designed to oppose toxic effects of oxidative radicals include superoxide dismutase, catalase, glutathione (GSH) and glutathione peroxidase. The following experiments determined whether CVB3-challenged mice given Ambrotose | by parenteral injections had enhanced GSH levels in their splenic monocytes/macrophages, compared to the CVB3-challenged virus controls, as one possible explanation for how Ambrotose | contributed to recovery from pancreatitis. Data on free GSH levels in splenic monocytes/macrophages at six time points from all four groups of mice are presented in Table 5 . Ambrotose | administration to normal mice did not alter GSH levels. Splenic macrophages/monocytes from mice previously challenged with CVB3 m generally, i.e., five of six sample times, had lower GSH levels than those found in the normal group of mice at each time of sacrifice. Virus-infected mice administered Ambrotose | contained splenic macrophages/ monocytes with significantly enhanced GSH levels in the same five of six sample times cited above. The increased GSH levels in splenic macrophages/monocytes taken from the virus-challenged mice given Ambrotose | ranged from about 9 to 97% above the levels found in virus-control mice. We conclude that Ambrotose | administration to CVB3m-inoculated mice significantly increased GSH levels in their splenocytes.
Ambrotose ~ Injections Increased the Level of Free Glutathione [GSH] in Splenic Macrophages. Many viruses
DISCUSSION
The data show that inoculation of mice with a CVB3 strain can result in long term pancreatitis in some mice whereas other mice appear to resolve the acute pancreatitis, i.e., the destruction of acinar cells occurred over a range of >90% destroyed to none destroyed in groups of mice sacrificed at times up to 8 months post-CVB3 inoculation. No mice died during the course of this experiment and some presented with near total pancreatic acinar cell destruction at their time of sacrifice, including one mouse at eight months post virus-challenge. The latter mouse was from the group that received weekly i.p. Ambrotose | injections during the 8 month experiment, suggesting that this mouse, and some other mice in the Ambrotose| groups, were incapable of deriving any ameliorative benefit for their pancreata from the glyconutritional mixture. It is not known why some mice, like some humans (30), do not derive health benefits from dietary nutritional supplements. In contrast, several types of statistical analyses (Chi square, Tukey's Multiple Comparison or Student's t test) of the data on all mice or on specific time-ofsacrifice groups of CVB3-challenged Ambrotose| -jected versus control groups showed there was a significant reduction in acinar cell destruction and increased glutathione levels in splenic macrophages in glyconutrient (10) * Half of all mice were rejected i.p. with Ambrotose | (10mg/kg body weight) dissolved in DPBS and the remaining half received DPBS beginning on day -7 and continuing approximately every 7 days through day 241 p.i.; inoculations were in 0.2 ml. On day 0, half of each of the latter two groups were challenged with CVB3 m at 5x105 pfu/mouse in 0.2 ml by the i.p. route. Seven mice from each group were sacrificed on a given day, blood was processed to obtain sera for assay of glucose. 1 Glucose concentrations were assessed by an Ames Glucometer 3. :1: indicates that one or more samples within the group contained <15mg/dl glucose. 
* Adolescent male CD-1 mice were inoculated by i.p. route with 5Xl 05 plaque-forming units of purified CVB3r, on day 0. Mice were injected i.p. with 1•mg/kgb•dyweight•fAmbr•t•se| p.i. Relative free GSH levels, fluorescence units as a function of mBCL binding, were measured 5-20 times per each of the splenic cell samples from 7 individual mice per sample through day 133 p.i.; on day 248 p.i. there were 8, 9, 8 and 10 mice in the N, N + A, VC and V + A groups, respectively. Low mean units reported for samples taken on day 28 were due to a technical problem of cell plating which was consistent in all four samples to yield reliable data. Numbers in parenthesis represent the independent number of GSH measurements made in random cells obtained from that group of mice. Values are significantly different from the values of the virus control group (p<0.05) on that day of assay by Tukey's Multiple Comparison Test. treated mice. Thus, these data lead to the conclusion that some mice benefited in their recovery from pancreatitis due to their treatment with Ambrotose | Data presented herein suggest one potential recovery mechanism that may be promoted by Ambrotose | via an unknown mechanism, is to increase levels of glutathione, a major antioxidant in cells. Previous studies (Barhoumi et al., 1997 , Busbee et al., 1999 showed that Ambrotose | provided protection against chemical depletion of glutathione in rat liver cells by patulin, a sulfhydrylbinding reagent, via an unknown blocking mechanism. Competitive binding of patulin by a glyconutrient(s) in the mixture comprising Ambrotose | is one possible explanation.
Blocking glutathione depletion could significantly contribute to prevention of the oxidant activity from nitric oxide (NO) induced by CVB3 replication in cells or from inflammatory cells attracted to the site of replication of the virus in an animal, e.g., the heart or pancreas (Huber et al., 1998) . Inhibitors of nitric oxide synthetase lead to increased titers of virus in the heart and higher mortality in CVB3-infected mice (Hiraoka et al., 1996; Lowenstein et al., 1996) , thus NO must play an unknown role in controlling the extent of virus replication in tissues in vivo. However, NO can react with oxygen to result in free radical formation and can participate in tissue injury. Mice challenged with encephalomyocarditis virus, a naturally-occurring murine picornavirus, can develop diabetes mellitus type 1, but treatment of these mice with an inhibitor of inducible NO synthetase reduced the incidence of diabetes (Hirasawa et al., 1997) . Thus, i.p. injectior~of Ambrotose | to increase, maintain, or restore intracellular levels of antioxidants such as glutathione would provide time for regeneration of acinar cells to replace those destroyed by virus-induced direct (replicative) and indirect (inflammatory) mechanisms.
The benefits of adding nutraceuticals to the diets of some patients with either types of diabetes have been previously described . Some parameters of that study showed significant improvements with the dietary supplement whereas others showed minimal improvement similar to the outcome for mice described in the present study. The complexity of health parameters in individuals (mice or humans) would dictate that a broad range of outcomes is likely, as was found. Further work is needed to define why some individuals respond more favorable to glyconutritional supplementation than others.
Gauntt, C J: Roles of the humoral response in CVBinduced disease, in The Coxsackie B Viruses, Volume 223, Current Topics in Microbiology and Immunology, edited by Tracy, S, Chapman, N and Mahy, B, Berlin, Springer, 1997, pp. 259-282. 
